A Cell-Specific Nuclear Factor-Kappa B-Activating Gene Expression Strategy for Delivering Cancer Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Current immunotherapies face limitations due to cancer cell-specific antigens.
• Personalized cancer vaccines are a promising area, aided by neoantigen identification.
• Targeting cancer cells specifically is crucial for effective immunotherapy.

Purpose of the Study:

• To evaluate a novel immunotherapy strategy.
• To develop a cancer cell-specific gene expression technique for artificial neoantigens.
• To assess the potential of a nuclear factor-kappa B (NF-κB)-activating gene expression vector for cancer treatment.

Main Methods:

• Developed a NF-κB-activating gene expression (Nage) vector with a NF-κB-specific promoter (DMP).
• Engineered the Nage vector to express proteins/peptides on cancer cell surfaces as artificial neoantigens.
• Packaged the Nage vector in adeno-associated virus (AAV) for in vivo delivery.

Main Results:

• Demonstrated widespread over-activation of NF-κB RelA exclusively in cancer cells.
• Confirmed specific expression of proteins/peptides on various cancer cell surfaces using the Nage vector.
• Showed significant inhibition or eradication of in vivo tumors via intravenously injected recombinant AAV-Nage vectors.

Conclusions:

• The Nage vector system enables cancer cell-specific expression of artificial neoantigens.
• This targeted immunotherapy approach effectively stimulates an anti-tumor immune response.
• Recombinant AAV-mediated delivery of the Nage vector shows potent in vivo tumor inhibition and eradication capabilities.